Efavirenz Tablets and Sirturo Tablets
Determining the interaction of Efavirenz Tablets and Sirturo Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of bedaquiline, which is primarily metabolized by CYP450 3A4 to the major N-monodesmethyl metabolite, M2. Because M2 is 4- to 6-fold less active than the parent drug in terms of antimycobacterial potency, the interaction may diminish the therapeutic effect of bedaquiline. In healthy volunteers, administration of a single 300 mg dose of bedaquiline in combination with rifampin 600 mg once daily for 21 days reduced bedaquiline systemic exposure (AUC) by 52% compared to administration alone. Another study involving healthy volunteers revealed a 20% decrease in the AUC and no change in the Cmax of bedaquiline (400 mg once) when administered with efavirenz (600 mg once daily for 27 days). MANAGEMENT: The concomitant use of bedaquiline with potent or moderate CYP450 3A4 inducers should generally be avoided. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 "Product Information. Sirturo (bedaquiline)." Janssen Pharmaceuticals, Titusville, NJ.
Professional:GENERALLY AVOID: Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of bedaquiline, which is primarily metabolized by CYP450 3A4 to the major N-monodesmethyl metabolite, M2. Because M2 is 4- to 6-fold less active than the parent drug in terms of antimycobacterial potency, the interaction may diminish the therapeutic effect of bedaquiline. In healthy volunteers, administration of a single 300 mg dose of bedaquiline in combination with rifampin 600 mg once daily for 21 days reduced bedaquiline systemic exposure (AUC) by 52% compared to administration alone. Another study involving healthy volunteers revealed a 20% decrease in the AUC and no change in the Cmax of bedaquiline (400 mg once) when administered with efavirenz (600 mg once daily for 27 days).
MANAGEMENT: The concomitant use of bedaquiline with potent or moderate CYP450 3A4 inducers should generally be avoided.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Sirturo (bedaquiline)." Janssen Pharmaceuticals, Titusville, NJ.
Generic Name: efavirenz
Brand name: Sustiva
Synonyms: Efavirenz
Generic Name: bedaquiline
Brand name: Sirturo
Synonyms: Bedaquiline, Bedaquiline Fumarate
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Efavirenz Tablets-Sitagliptin
- Efavirenz Tablets-Sitagliptin and metformin
- Efavirenz Tablets-Sitagliptin and Metformin Extended-Release Tablets
- Efavirenz Tablets-Sitagliptin and Metformin Tablets
- Efavirenz Tablets-Sitagliptin and simvastatin
- Efavirenz Tablets-Sitagliptin Phosphate
- Sirturo Tablets-Efavirenz, emtricitabine, and tenofovir
- Sirturo Tablets-Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate
- Sirturo Tablets-Efavirenz, lamivudine, and tenofovir
- Sirturo Tablets-Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate
- Sirturo Tablets-Effaclor Duo
- Sirturo Tablets-Effer-K